Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Table 2 Patient disposition based on cytogenetic risk status

	Standard risk^a		High risk^a,b
Treatment discontinuation, n (%)^c	D-Vd (n = 137)	Vd (n = 136)	D-Vd (n = 40)	Vd (n = 34)
Patients who discontinued treatment	108 (79)	62 (46)	33 (83)	17 (50)
Reason for discontinuation
Progressive disease	86 (63)	34 (25)	27 (68)	12 (35)
Adverse event	11 (8)	15 (11)	5 (13)	3 (9)
Noncompliance with study drug^d	5 (4)	5 (4)	0	1 (3)
Withdrawal by patient	1 (1)	6 (4)	0	1 (3)
Death	2 (1)	2 (1)	1 (3)	0
Physician decision	3 (2)	0	0	0

D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, FISH fluorescence in situ hybridization
^aBased on FISH/karyotyping
^bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
^cSafety population
^dBased on reason “Patient refused to further study treatment” at “End of treatment”

ISSN: 1756-8722